Analyses of outcome in association with various parameters
| . | No. of patients . | No. of responders (%) . | |
|---|---|---|---|
| 5 wk . | 6 mo . | ||
| Sex | |||
| Female | 14 | 11 (79) | 10 (71) |
| Male | 19 | 10 (53) | 7 (37) |
| P | — | .16 | .08 |
| Age at CTL infusion | |||
| Younger than 16 y | 10 | 7 (70) | 5 (50) |
| 16 to 49 y | 9 | 6 (67) | 5 (56) |
| 50 y or older | 14 | 8 (57) | 7 (50) |
| P trend | — | .51 | .98 |
| Time to PTLD from transplantation | |||
| Fewer than 2 y | 14 | 9 (64) | 9 (64) |
| 2 y or longer | 19 | 12 (63) | 8 (42) |
| P | — | .999 | .30 |
| Single vs multiple tumor sites | |||
| Single site | 4 | 3 (75) | 3 (75) |
| Multiple sites | 29 | 18 (62) | 14 (48) |
| P | — | .999 | .60 |
| Sites involved | |||
| Nodal | 11 | 8 (73) | 5 (45) |
| Extranodal | 15 | 9 (60) | 8 (53) |
| Both | 7 | 4 (57) | 4 (57) |
| P | — | .72 | .999 |
| Histologic type of PTLD | |||
| Hyperplastic | 5 | 4 (80) | 3 (60) |
| Hodgkin lymphoma | 5 | 5 (100) | 4 (80) |
| Polymorphic | 9 | 5 (56) | 4 (44) |
| Monomorphic | 14 | 7 (50) | 6 (43) |
| P | — | .23 | .61 |
| Clonality of tumor* | |||
| Polyclonal | 7 | 4 (57) | 2 (29) |
| Monoclonal† | 10 | 8 (80) | 8 (80) |
| Negative | 2 | 2 (100) | 2 (100) |
| P | — | .78 | .80 |
| Percentage of CD4 cells in infused CTL lines | |||
| Less than 1% | 12 | 3 (25) | 2 (17) |
| 1% to 4.9% | 9 | 7 (78) | 5 (56) |
| 5% or more | 12 | 11 (92) | 10 (83) |
| P trend | — | .001 | .001 |
| Number of HLA matches at HLA A, B, and DR loci | |||
| 2/6 | 3 | 2 (67) | 1 (33) |
| 3/6 | 13 | 7 (54) | 5 (38) |
| 4/6 | 7 | 3 (43) | 3 (43) |
| 5/6 | 10 | 9 (90) | 8 (80) |
| P trend | — | .17 | .048 |
| . | No. of patients . | No. of responders (%) . | |
|---|---|---|---|
| 5 wk . | 6 mo . | ||
| Sex | |||
| Female | 14 | 11 (79) | 10 (71) |
| Male | 19 | 10 (53) | 7 (37) |
| P | — | .16 | .08 |
| Age at CTL infusion | |||
| Younger than 16 y | 10 | 7 (70) | 5 (50) |
| 16 to 49 y | 9 | 6 (67) | 5 (56) |
| 50 y or older | 14 | 8 (57) | 7 (50) |
| P trend | — | .51 | .98 |
| Time to PTLD from transplantation | |||
| Fewer than 2 y | 14 | 9 (64) | 9 (64) |
| 2 y or longer | 19 | 12 (63) | 8 (42) |
| P | — | .999 | .30 |
| Single vs multiple tumor sites | |||
| Single site | 4 | 3 (75) | 3 (75) |
| Multiple sites | 29 | 18 (62) | 14 (48) |
| P | — | .999 | .60 |
| Sites involved | |||
| Nodal | 11 | 8 (73) | 5 (45) |
| Extranodal | 15 | 9 (60) | 8 (53) |
| Both | 7 | 4 (57) | 4 (57) |
| P | — | .72 | .999 |
| Histologic type of PTLD | |||
| Hyperplastic | 5 | 4 (80) | 3 (60) |
| Hodgkin lymphoma | 5 | 5 (100) | 4 (80) |
| Polymorphic | 9 | 5 (56) | 4 (44) |
| Monomorphic | 14 | 7 (50) | 6 (43) |
| P | — | .23 | .61 |
| Clonality of tumor* | |||
| Polyclonal | 7 | 4 (57) | 2 (29) |
| Monoclonal† | 10 | 8 (80) | 8 (80) |
| Negative | 2 | 2 (100) | 2 (100) |
| P | — | .78 | .80 |
| Percentage of CD4 cells in infused CTL lines | |||
| Less than 1% | 12 | 3 (25) | 2 (17) |
| 1% to 4.9% | 9 | 7 (78) | 5 (56) |
| 5% or more | 12 | 11 (92) | 10 (83) |
| P trend | — | .001 | .001 |
| Number of HLA matches at HLA A, B, and DR loci | |||
| 2/6 | 3 | 2 (67) | 1 (33) |
| 3/6 | 13 | 7 (54) | 5 (38) |
| 4/6 | 7 | 3 (43) | 3 (43) |
| 5/6 | 10 | 9 (90) | 8 (80) |
| P trend | — | .17 | .048 |